最新藥物分子砌塊-2021/08 - 樂研試劑

<cite id="5fd55"></cite>

<menuitem id="5fd55"></menuitem>

<var id="5fd55"><strike id="5fd55"><listing id="5fd55"></listing></strike></var>

<cite id="5fd55"><video id="5fd55"></video></cite><var id="5fd55"><strike id="5fd55"></strike></var>

<cite id="5fd55"></cite>

<menuitem id="5fd55"><dl id="5fd55"></dl></menuitem>

<menuitem id="5fd55"></menuitem>

<address id="5fd55"><listing id="5fd55"><ins id="5fd55"></ins></listing></address>

<var id="5fd55"></var>

<var id="5fd55"><strike id="5fd55"><listing id="5fd55"></listing></strike></var>

<ins id="5fd55"><span id="5fd55"></span></ins><menuitem id="5fd55"><dl id="5fd55"></dl></menuitem>

<var id="5fd55"><span id="5fd55"><var id="5fd55"></var></span></var>

<menuitem id="5fd55"></menuitem>

<var id="5fd55"></var><var id="5fd55"></var>

<var id="5fd55"></var>

<var id="5fd55"><strike id="5fd55"><listing id="5fd55"></listing></strike></var>

搜索

購物車

最新藥物分子砌塊-2021/08 2021/08/06 16:16:03

新品推薦 - 2021 年 08 月

Antibody-Drug conjugates (ADCs) have become a promising targeted therapy strategy that combines the specificity, favorable pharmacokinetics and biodistributions of antibodies with the destructive potential of highly potent drugs^[1].
ADCs consist of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker. The monoclonal antibodies lead the drug precursors to the target cancer cells, in which the prodrugs can be chemically or enzymatically converted to drugs in their active forms . Conjugating cytotoxins to monoclonal antibodies that specifically tie to tumor cell surface antigens enables the drugs to be target-delivered to cancer cells and leaves normal cells unaffected. More important, many of the cytotoxic drugs that are too toxic for use in traditional chemotherapy can also be used in the construction of antibody-drug conjugates. The linkers are essential parts of antibody-drug conjugates, which account for stability in circulation,good pharmacokinetics and efficient release of toxic drugs in the tumor cells^[2,3,4].

A series of medicinal products containing 1,3,4-oxadiazole has been firmly incorporated in medical practice.

產品編號: 1099391

CAS: 138529-46-1
產品編號: 1175659

CAS: 1433997-01-3
產品編號: 1178252

CAS: 1537170-85-6
產品編號: 1175811

CAS:2222981-71-5
產品編號: 1054454

CAS: 159857-81-5
產品編號: 1175649

CAS: 2149584-03-0

免費熱線：400-821-0725

官方網址： www.vecc-sepa.org 技術支持郵箱： tech@leyan.com 產品咨詢郵箱： product@leyan.com

聲明：樂研產品僅用于科學研究，我們不為任何個人用途提供產品與服務。

上一篇：最新藥物分子砌塊-2021/08 下一篇：最新藥物分子砌塊-2021/08

80000+分子砌塊

現貨供應

10年研發經驗

專業護航

7天無理由退換

售后無憂

100%質量檢測

品質保障

100%產品包郵

無需湊單

上海皓鴻生物醫藥科技有限公司

關于樂研
會員與積分

訂購指南
文檔和參考資料

售后和支持

尊敬的樂研客戶您好，
請您選擇所在區域，我們將轉接對應客服為您服務！

上海企業高校江蘇企業高校浙江企業高校北京企業高校天津企業高校河北河北廣東企業高校深圳深圳福建福建山東山東山西山西安徽安徽湖北湖北湖南湖南江西江西川渝企業高校陜西陜西甘肅甘肅黑龍江黑龍江吉林吉林遼寧遼寧云南云南貴州貴州廣西廣西海南海南寧夏寧夏河南河南內蒙古內蒙古新疆新疆青海青海

久久久久精品国产麻豆